Vivus announced this morning that an FDA advisory committee is tentatively scheduled to take a look at its diet drug Qnexa on Thursday, July 15th.
One of the many things I think is great about Twitter is the direct contact it gives me with a handful of biopharma reporters who are using it.
Using coded email messages referring to securities and money as "frequent flyer miles" and "potatoes," a high-ranking UBS investment banker and a trader made $870,000 in illegal profits from trades on tips about six UBS healthcare client acquisitions, U.S. prosecutors said.
Carl Icahn, reputed to be a late-riser, woke up to good news and bad news today.
Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.
Hospitals and drug makers, which supported the final healthcare legislation, would be clear beneficiaries, analysts say, even if the outlook for insurers was less certain, the NY Times reports.
House Democrats are pushing to pass the health care bill as Pres. Obama seeks to rally recalcitrant congresspeople. Which stocks and sectors actually stand to benefit from the bill? Les Funtleyder, health care strategist at Miller Tabak, Jason Gurda, managed care analyst at Leerink Swann and Ralph Giacobbe, analyst at Credit Suisse First Boston offered their insights and investment recommendations.
The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.
Speaker Pelosi is as good as it gets in wrestling votes for legislation she favors. She is the female version of that titan, Tip O'Neill (D. Mass.) who famously said, "All politics is local." But as good as she is, the Speaker seems to have come up short with the necessary votes to get the Senate version of the health care bill passed in the House of Representatives.
I can hear the commercial now. “Underarm protection that literally makes you feel more like a man.”
Of course, I'm off the day all heck breaks loose on the beat and stocks are making big moves all over the place.
President Obama is going all in on the health care plan. He postponed an overseas trip to be on hand for a hoped for vote on the plan this coming Friday.
Tomorrow is the day the agency is scheduled to announce if the first once-a-week diabetes treatment, a rejiggered version of the now twice-a-day Byetta, can come to market.
Stocks eked out a modest gain Tuesday as this one-year anniversary of the March 2009 lows brought a mix of profit-taking and optimism. Citigroup surged while Cisco slipped.
On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.
Stocks clawed higher after a lower open Tuesday as this one-year anniversary of the March 2009 lows brought a mix of profit-taking and optimism. Cisco sold off after the company announced its much-hyped high-speed router.
Stocks tried to claw higher after a lower open Tuesday amid some profit taking on this one-year anniversary of the March 2009 lows.
U.S. stock index futures pointed to a slightly lower open for Wall Street Monday, with investors expected to pause after last week's rally caused by better-than-expected nonfarm payrolls data.
Stocks ended mixed Monday in tepid trading as investors took a breather after last week's rally. McDonald's and Research In Motion advanced.
It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards.